Ajanta Pharma share news, announcements and annual reports
NSE: AJANTPHARMBSE: 532331Pharmaceuticals & BiotechnologyMid Cap
Ajanta Pharma Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2000 on NSE, Jun 2000 on BSE
Last close ₹3,396.30down ₹112.50 (3.21%)BSE ₹3,394.65
Share price at the NSE close on 2 Nov 2026. Previous close ₹3,508.80.
2 Nov: open ₹3,477.30, high ₹3,477.80, low ₹3,321.00
52-week range of traded prices to 2 Nov 2026
₹2,445.80Low, 18 Nov 2025₹3,796.00High, 18 Aug 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹42,440 Cr236th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 33.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 8.74
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.77%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 27.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 30.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,91,99660.7% delivered
Ajanta Pharma board meetings
103 filed, newest first. Page 2 of 3.
Jul 2018
31 Jul · Board meeting
20 Jul · Board meeting
May 2018
2 May · Board meeting
Apr 2018
20 Apr · Board meeting
Jan 2018
Oct 2017
Jul 2017
May 2017
3 May · Board meeting
Apr 2017
Mar 2017
Jan 2017
Oct 2016
Jul 2016
Apr 2016
Mar 2016
Jan 2016
Oct 2015
Jul 2015
Apr 2015
24 Apr · Board meeting
To inter alia: 1. Consider and approve the audited Financial Results of the Company for the quarter and year ended March 31, 2015; 2. Consider and approve Financial Statements for the year ended March 31, 2015 3. Recommend dividend, if any, on equity shares of the Company for the financial year 2014-15.
Jan 2015
Oct 2014
16 Oct · Board meeting
To consider and approve, inter alia, the Unaudited Financial Results for the second quarter and half year ended 30th September, 2014.
Jul 2014
21 Jul · Board meeting
To consider and approve, inter alia, the Unaudited Financial Results for the first quarter ended June 30, 2014.
Jun 2014
12 Jun · Board meeting
For considering appointment of two Additional Directors of the Company.
Apr 2014
Jan 2014
17 Jan · Board meeting
To consider and approve, inter alia, the Unaudited Financial Results for the third quarter ended December 31, 2013.
Oct 2013
18 Oct · Board meeting
To consider and approve, inter alia, the Unaudited Financial Results for the second quarter and half year ended September 30, 2013.
Jul 2013
18 Jul · Board meeting
(1) To consider and approve, inter alia, the Unaudited Financial Results for the first quarter ended June 30, 2013. (2) To consider Bonus issue of shares.
Apr 2013
19 Apr · Board meeting
To consider and approve, inter alia : (1) The audited Financial Results for the year ended March 31, 2013 and (2) Recommending dividend, if any, on equity shares of the Company for the Financial year 2012-13.
Jan 2013
11 Jan · Board meeting
To consider and approve, inter alia, the Unaudited Financial Results for the third quarter ended December 31, 2012.
Oct 2012
12 Oct · Board meeting
To consider and approve, inter-alia, the Unaudited Financial Results for the second quarter ended September 30, 2012.
Jul 2012
9 Jul · Board meeting
To consider and approve, inter alia, the Unaudited Financial Results for the first quarter ended June 30, 2012.
Apr 2012
16 Apr · Board meeting
To consider and approve, inter alia: (1) The audited Financial Results for the year ended March 31, 2012; (2) Recommending dividend, if any, on equity shares of the Company for the Financial year 2011-12 and (3) Sub-division of shares.
Jan 2012
12 Jan · Board meeting
To consider and approve, inter alia, the Unaudited Financial Results for the third quarter ended December 31, 2011.
Oct 2011
13 Oct · Board meeting
To consider and approve, inter-alia, the Unaudited Financial Results for the second quarter ended September 30, 2011.
Jul 2011
18 Jul · Board meeting
To consider and approve, inter alia, the Unaudited Financial Results for the first quarter ended June 30, 2011.
Apr 2011
19 Apr · Board meeting
To consider and approve, inter alia, the audited Financial Results for the year ended March 31, 2011 and recommending dividend, if any, on equity shares of the Company for the Financial Year 2010-11.
Jan 2011
10 Jan · Board meeting
To consider and approve, inter alia, the Unaudited Financial Results for the third quarter ended December 31, 2010.
Oct 2010
11 Oct · Board meeting
To consider and approve, inter-alia, the Unaudited Financial Results for the second quarter and half year ended September 30, 2010.
Jul 2010
19 Jul · Board meeting
To consider and approve, inter alia, the Unaudited Financial Results for the quarter ended June 30, 2010.
Apr 2010
26 Apr · Board meeting
To consider and approve, inter alia, the audited Financial Results for the year ended March 31, 2010 and recommending dividend, if any, on equity shares of the Company for the Financial Year 2009-10.
Jan 2010
18 Jan · Board meeting
Meeting on 29 Jan 2010: “Unaudited Financial Results for the qtr ended Dec 31, 2009”
Oct 2009
20 Oct · Board meeting
To consider and approve the Unaudited Financial Results for the second quarter and half year ended on September 30, 2009 and consider the proposal for the buy-back of shares.
Jul 2009
16 Jul · Board meeting
To consider and approve the Unaudited Financial Results for the first quarter ended on June 30, 2009.
May 2009
6 May · Board meeting
To consider and approve, inter alia, the audited Financial Results for the year ended March 31, 2009 and recommending dividend, if any, on equity shares of the Company for the Financial Year 2008-09.
Jan 2009
5 Jan · Board meeting
Meeting on 29 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”
Oct 2008
3 Oct · Board meeting
To consider and approve the Unaudited Financial Results for the second quarter and half year ended on September 30, 2008.
Jul 2008
17 Jul · Board meeting
Meeting on 30 Jul 2008: “Unaudited Financial Results for the Qtr ended June 30, 2008”
Apr 2008
16 Apr · Board meeting
To consider and approve, inter alia, the audited Financial Results for the year ended March 31, 2008 and recommending dividend, if any, on equity shares of the Company for the Financial Year 2007 -08.
Oct 2007
11 Oct · Board meeting
To consider and approve the Unaudited Financial Results for the second quarter and half year ended on September 30, 2007.